Worldwide Study Finder

Phase 4Not yet recruitingINTERVENTIONAL

Mazdutide for Adults With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial (DREAM-PRE)

ClinicalTrials.gov · NCT07654062 · Registry updated: 2026-06-17

Condition / research focus: Prediabetes; Impaired Fasting Glucose; Impaired Glucose Tolerance (Prediabetes)
Sponsor: Shandong Provincial Hospital
Countries with listed sites: China
Registry dates and results: Start: 2026-07. Completion: 2029-07 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Mazdutide (drug)
Placebo (drug)
Standardized Lifestyle Intervention (behavioral)

Where the study takes place — 1 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Shandong Provincial Hospital Affiliated to Shandong First Medical UniversityJinan, Shandong, China

Phase 3CompletedINTERVENTIONAL

Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight

ClinicalTrials.gov · NCT06588283 · Registry updated: 2026-06-17

Condition / research focus: Psoriasis; Obesity
Sponsor: Eli Lilly and Company
Countries with listed sites: Puerto Rico · United States
Registry dates and results: Start: 2024-09-30. Completion: 2026-06-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Ixekizumab (drug) — also listed as: LY2439821
Tirzepatide (drug) — also listed as: LY3298176

Where the study takes place — 72 listed sites

Total Skin & Beauty Dermatology Center, PC DBA Total Dermatology
Birmingham, Alabama, United States
Site recruitment: Not reported
Medical Dermatology Specialists
Phoenix, Arizona, United States
Site recruitment: Not reported
Scottsdale Clinical Trials
Scottsdale, Arizona, United States
Site recruitment: Not reported
Yuma Clinical Trials
Yuma, Arizona, United States
Site recruitment: Not reported
Johnson Dermatology
Fort Smith, Arkansas, United States
Site recruitment: Not reported
California Dermatology & Clinical Research Institute
Encinitas, California, United States
Site recruitment: Not reported
First OC Dermatology Research Inc
Fountain Valley, California, United States
Site recruitment: Not reported
Avance Clinical Trials
Laguna Niguel, California, United States
Site recruitment: Not reported
Metropolis Dermatology
Los Angeles, California, United States
Site recruitment: Not reported
Dermatology Research Associates
Los Angeles, California, United States
Site recruitment: Not reported
Northridge Clinical Trials
Northridge, California, United States
Site recruitment: Not reported
Cura Clinical Research - Oxnard
Oxnard, California, United States
Site recruitment: Not reported
Integrative Skin Science and Research - Location 2
Sacramento, California, United States
Site recruitment: Not reported
Therapeutics Clinical Research
San Diego, California, United States
Site recruitment: Not reported
Life Clinical Trials
Coral Springs, Florida, United States
Site recruitment: Not reported
Alliance for Multispecialty Research, LLC
Fort Myers, Florida, United States
Site recruitment: Not reported
NeoClinical Research
Hialeah, Florida, United States
Site recruitment: Not reported
Skin Care Research
Hollywood, Florida, United States
Site recruitment: Not reported
Encore Medical Research
Hollywood, Florida, United States
Site recruitment: Not reported
Solutions Through Advanced Research
Jacksonville, Florida, United States
Site recruitment: Not reported
Deluxe Health Center
Miami Lakes, Florida, United States
Site recruitment: Not reported
Renstar Medical Research
Ocala, Florida, United States
Site recruitment: Not reported
Leading Edge Dermatology
Plantation, Florida, United States
Site recruitment: Not reported
International Clinical Research - Sanford
Sanford, Florida, United States
Site recruitment: Not reported
Nodal Medical Center
Tampa, Florida, United States
Site recruitment: Not reported
Palm Harbor Dermatology PA d/b/a TrueBlue Clinical Research
Tampa, Florida, United States
Site recruitment: Not reported
DeNova Research
Chicago, Illinois, United States
Site recruitment: Not reported
Oak Dermatology
Naperville, Illinois, United States
Site recruitment: Not reported
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana, United States
Site recruitment: Not reported
The Indiana Clinical Trials Center, PC
Plainfield, Indiana, United States
Site recruitment: Not reported
Equity Medical - Bowling Green
Bowling Green, Kentucky, United States
Site recruitment: Not reported
DelRicht Research
Baton Rouge, Louisiana, United States
Site recruitment: Not reported
Care Access - Lake Charles (Bayou Pines)
Lake Charles, Louisiana, United States
Site recruitment: Not reported
Dermatology and Skin Cancer Specialists, LLC
Rockville, Maryland, United States
Site recruitment: Not reported
Lawrence J. Green, MD, LLC
Rockville, Maryland, United States
Site recruitment: Not reported
Great Lakes Research Group, Inc.
Bay City, Michigan, United States
Site recruitment: Not reported
The Derm Institute of West Michigan
Caledonia, Michigan, United States
Site recruitment: Not reported
MI Skin Innovations
Northville, Michigan, United States
Site recruitment: Not reported
Las Vegas Dermatology
Las Vegas, Nevada, United States
Site recruitment: Not reported
Skin Cancer and Dermatology Institute - Reno
Reno, Nevada, United States
Site recruitment: Not reported
ActivMed Practices & Research, LLC.
Portsmouth, New Hampshire, United States
Site recruitment: Not reported
Psoriasis Treatment Center of Central New Jersey
East Windsor, New Jersey, United States
Site recruitment: Not reported
Care Access - Hoboken
Hoboken, New Jersey, United States
Site recruitment: Not reported
Equity Medical
New York, New York, United States
Site recruitment: Not reported
Mount Sinai Doctors - East 85th Street
New York, New York, United States
Site recruitment: Not reported
Onsite Clinical Solutions - Huntersville
Huntersville, North Carolina, United States
Site recruitment: Not reported
Red River Research Partners
Fargo, North Dakota, United States
Site recruitment: Not reported
Optima Research - Boardman
Boardman, Ohio, United States
Site recruitment: Not reported
Dermatologists of Southwest Ohio
Mason, Ohio, United States
Site recruitment: Not reported
Oregon Medical Research Center
Portland, Oregon, United States
Site recruitment: Not reported
Oregon Dermatology and Research Center
Portland, Oregon, United States
Site recruitment: Not reported
Dermatology Associates of Plymouth Meeting
Plymouth Meeting, Pennsylvania, United States
Site recruitment: Not reported
Columbia Dermatology & Aesthetics
Columbia, South Carolina, United States
Site recruitment: Not reported
International Clinical Research - Tennessee LLC
Murfreesboro, Tennessee, United States
Site recruitment: Not reported
DelRicht Research - Thompson's Station
Smyrna, Tennessee, United States
Site recruitment: Not reported
Tekton Research - Westlake Drive
Austin, Texas, United States
Site recruitment: Not reported
Bellaire Dermatology Associates
Bellaire, Texas, United States
Site recruitment: Not reported
Modern Research Associates, PLLC
Dallas, Texas, United States
Site recruitment: Not reported
Austin Institute for Clinical Research
Pflugerville, Texas, United States
Site recruitment: Not reported
Progressive Clinical Research
San Antonio, Texas, United States
Site recruitment: Not reported
Texas Dermatology and Laser Specialists
San Antonio, Texas, United States
Site recruitment: Not reported
Dermatology Clinical Research Center of San Antonio
San Antonio, Texas, United States
Site recruitment: Not reported
Tanner Clinic
Layton, Utah, United States
Site recruitment: Not reported
Care Access - Arlington
Arlington, Virginia, United States
Site recruitment: Not reported
Care Access - Danville
Danville, Virginia, United States
Site recruitment: Not reported
Virginia Clinical Research, Inc.
Norfolk, Virginia, United States
Site recruitment: Not reported
Bellevue Dermatology Clinic
Bellevue, Washington, United States
Site recruitment: Not reported
Dermatology of Seattle
Burien, Washington, United States
Site recruitment: Not reported
SCB Research Center
Bayamón, Puerto Rico
Site recruitment: Not reported
Office of Dr. Alma M. Cruz
Carolina, Puerto Rico
Site recruitment: Not reported
GCM Medical Group, PSC - Hato Rey Site
San Juan, Puerto Rico
Site recruitment: Not reported
Mindful Medical Research
San Juan, Puerto Rico
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1 / Phase 2Active, not recruitingINTERVENTIONAL

Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type 1 Diabetes

ClinicalTrials.gov · NCT05696366 · Registry updated: 2026-06-15

Condition / research focus: Type 1 Diabetes
Sponsor: University of California, San Diego
Countries with listed sites: United States
Registry dates and results: Start: 2024-09-09. Completion: 2028-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Sotagliflozin (drug)
Volagidemab (drug)

Where the study takes place — 1 listed sites

UC San Diego Altman Clinical & Translational Research Institute
La Jolla, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Effect of a Dietary Supplement on Hormones Involved in Appetite Regulation in Overweight and Obese Adults

ClinicalTrials.gov · NCT07240246 · Registry updated: 2026-06-15

Condition / research focus: GLP-1; Obesity &Amp; Overweight; Dietary Supplement
Sponsor: FFoQSI - Austrian Competence Centre for Feed and Food Quality, Safety & Innovation
Countries with listed sites: Austria
Registry dates and results: Start: 2025-10-24. Completion: 2026-05-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Intervention: Dietary Supplement with Plant Extracts (dietary_supplement)
Placebo (other)

Where the study takes place — 1 listed sites

Salzburger Universitätsklinikum
Salzburg, State of Salzburg, Austria
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableNot yet recruitingINTERVENTIONAL

Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation

ClinicalTrials.gov · NCT07382024 · Registry updated: 2026-06-12

Condition / research focus: Atrial Fibrillation Ablation; Persistent Atrial Fibrillation; Obesity & Overweight
Sponsor: National Taiwan University Hospital
Countries with listed sites: Taiwan
Registry dates and results: Start: 2026-06-16. Completion: 2028-07-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug)
Standard Care (in control arm) (other)

Where the study takes place — 1 listed sites

National Taiwan University Hospital Cardiovascular Center
Taipei, Taiwan
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1 / Phase 2Not yet recruitingINTERVENTIONAL

Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy

ClinicalTrials.gov · NCT07642635 · Registry updated: 2026-06-11

Condition / research focus: Duchenne Muscular Dystrophy (DMD)
Sponsor: Vanderbilt University Medical Center
Countries with listed sites: United States
Registry dates and results: Start: 2026-09-01. Completion: 2030-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide (Rybelsus®) (drug) — also listed as: Wegovy
Placebo (other)

Where the study takes place — 1 listed sites

Vanderbilt University Medical Center
Nashville, Tennessee, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableEnrolling by invitationOBSERVATIONAL

Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes

ClinicalTrials.gov · NCT07640139 · Registry updated: 2026-06-10

Condition / research focus: Obesity
Sponsor: Indiana University
Countries with listed sites: United States
Registry dates and results: Start: 2026-01-01. Completion: 2029-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Incretin-based therapies (GLP-1 and GLP-1/GIP) (drug) — also listed as: Zepbound, Tirzepatide, Wegovy, Semaglutide, Saxenda, Liraglutide

Where the study takes place — 1 listed sites

Indiana University
Indianapolis, Indiana, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Study to Investigate the Pharmacokinetics of Different Formulations and Safety of AZD5004 in Healthy Participants Aged 18 to 55 Years

ClinicalTrials.gov · NCT07455825 · Registry updated: 2026-06-10

Condition / research focus: Healthy Participants
Sponsor: AstraZeneca
Countries with listed sites: United States
Registry dates and results: Start: 2026-03-05. Completion: 2026-06-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

AZD5004 (drug)

Where the study takes place — 2 listed sites

Research Site
Glendale, California, United States
Site recruitment: Not reported
Research Site
Baltimore, Maryland, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableRecruitingINTERVENTIONAL

GLP-1 Therapy After Bariatric Surgery in Chinese Patients With Obesity

ClinicalTrials.gov · NCT07633639 · Registry updated: 2026-06-08

Condition / research focus: Obesity
Sponsor: China-Japan Friendship Hospital
Countries with listed sites: China
Registry dates and results: Start: 2026-05-01. Completion: 2028-05-01 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

LSG-Semaglutide group (combination_product)
LSG-Mazdutide group (combination_product)
LSG-Tirzepatide group (combination_product)
LSG group (procedure)

Where the study takes place — 1 listed sites

China-Japan Friendship Hospital
Beijing, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Antidiabetic Medications and Risk of Cancer

ClinicalTrials.gov · NCT07628556 · Registry updated: 2026-06-05

Condition / research focus: Cancer
Sponsor: University of Pecs
Countries with listed sites: Hungary
Registry dates and results: Start: 2025-03-15. Completion: 2025-12-30 (may be estimated). No results posted in this registry response.

Products and interventions (11)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Metformin (drug)
sulphonylurea (drug)
DPP-4 inhibitor (drug)
GLP-1 Receptor Agonists (drug)
SGLT-2 inhibitor (drug)
insulin (drug)
MET + SU (drug)
MET + DPP-4 inhibitor (drug)
MET + GLP-1RA (drug)
MET + SGLT2i (drug)
MET + INS (drug)

Where the study takes place — 1 listed sites

Pécs
Pécs, Hungary
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2RecruitingINTERVENTIONAL

Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease

ClinicalTrials.gov · NCT06976853 · Registry updated: 2026-06-05

Condition / research focus: Crohn Disease (CD)
Sponsor: Washington University School of Medicine
Countries with listed sites: United States
Registry dates and results: Start: 2025-05-13. Completion: 2028-08 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug)
Standard of care treatment (drug)

Where the study takes place — 3 listed sites

Cedars-Sinai Medical Center
Beverly Hills, California, United States
Site recruitment: Not yet recruiting
Washington University School of Medicine
St Louis, Missouri, United States
Site recruitment: Recruiting
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 1 / Phase 2Enrolling by invitationINTERVENTIONAL

Role of Glucagon-like Peptide-1 Receptor Agonists in Menstrual Irregularities in Adolescent Females With Type 1 Diabetes Mellitus

ClinicalTrials.gov · NCT07319286 · Registry updated: 2026-06-05

Condition / research focus: Menstrual Irregularities; Type1 Diabetes Mellitus; Glucagon-Like Peptide-1 Receptor Agonists; Female Reproductive Health
Sponsor: Ain Shams University
Countries with listed sites: Egypt
Registry dates and results: Start: 2025-08-04. Completion: 2027-03 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Dulaglutide (drug)

Where the study takes place — 2 listed sites

Ain shams university
Cairo, Cairo Governorate, Egypt
Site recruitment: Not reported
Ain shams university
Cairo, Cairo Governorate, Egypt
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4Not yet recruitingINTERVENTIONAL

Tirzepatide on Atrial Fibrillation Recurrence After Catheter Ablation in Patients With Obesity and HFpEF

ClinicalTrials.gov · NCT07630454 · Registry updated: 2026-06-05

Condition / research focus: Atrial Fibrillation; Heart Failure With Preserved Ejection Fraction (HFpEF); Tirzepatide
Sponsor: Yunlong Wang
Countries with listed sites: China
Registry dates and results: Start: 2026-08-01. Completion: 2029-12-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug) — also listed as: Mounjaro
Structured Lifestyle Intervention (behavioral)

Where the study takes place — 1 listed sites

Beijing Anzhen Hospital
Beijing, Beijing Municipality, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2RecruitingINTERVENTIONAL

Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity

ClinicalTrials.gov · NCT07228741 · Registry updated: 2026-06-04

Condition / research focus: Acute Lymphoblastic Leukemia; Obesity
Sponsor: St. Jude Children's Research Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2026-04-23. Completion: 2028-11 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug)
Resistance Exercise (behavioral)
Lifestyle Counseling (behavioral)

Where the study takes place — 1 listed sites

St. Jude Children's Research Hospital
Memphis, Tennessee, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableNot yet recruitingINTERVENTIONAL

Effects of Inulin on Cardiometabolic Risk Factors in Individuals Using Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA ) Medications for Weight Loss

ClinicalTrials.gov · NCT07611552 · Registry updated: 2026-06-03

Condition / research focus: Obesity & Overweight
Sponsor: Huazhong University of Science and Technology
Countries with listed sites: China
Registry dates and results: Start: 2026-06. Completion: 2026-11 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

inulin (prebiotics) (dietary_supplement)
Placebo Comparator: maltodextrin (dietary_supplement)

Where the study takes place — 5 listed sites

The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture
Enshi, Hubei, China
Site recruitment: Not reported
Sinopharm Dongfeng General Hospital
Shiyan, Hubei, China
Site recruitment: Not reported
Huazhong University of Science and Technology
Wuhan, Hubei, China
Site recruitment: Not reported
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Site recruitment: Not reported
Xiangyang No.1 People's Hospital
Xiangyang, Hubei, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2RecruitingINTERVENTIONAL

Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes

ClinicalTrials.gov · NCT05822609 · Registry updated: 2026-06-02

Condition / research focus: Diabetic Kidney Disease; Type 1 Diabetes
Sponsor: University of Washington
Countries with listed sites: Canada · United States
Registry dates and results: Start: 2024-04-05. Completion: 2027-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide (drug)
Placebo (other)

Where the study takes place — 4 listed sites

University of Colorado Anschutz Medical Campus
Aurora, Colorado, United States
Site recruitment: Recruiting
University of Washington
Seattle, Washington, United States
Site recruitment: Recruiting
Providence Sacred Heart Medical Center
Spokane, Washington, United States
Site recruitment: Recruiting
Toronto General Hospital, University Health Network
Toronto, Ontario, Canada
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Effect of GLP-1 Analogue ROSE-010 on Appetite in Overweight and Obese Subjects

ClinicalTrials.gov · NCT06621017 · Registry updated: 2026-06-01

Condition / research focus: Obesity; Overweight
Sponsor: Rose Pharma Inc
Countries with listed sites: United States
Registry dates and results: Start: 2024-09-26. Completion: 2025-02-27 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

ROSE-010 99 mcg (drug)
Placebo (drug)
ROSE-010 150 mcg (drug)

Where the study takes place — 1 listed sites

Medpace Clinical Pharmacology
Cincinnati, Ohio, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2Not yet recruitingINTERVENTIONAL

SHIELD-T1D: Shingrix and GLP-1 Agonist for Beta-Cell Preservation in Recent-Onset Type 1 Diabetes.

ClinicalTrials.gov · NCT07614412 · Registry updated: 2026-05-29

Condition / research focus: Type 1 Diabetes Mellitus
Sponsor: Ministry of Health, Saudi Arabia
Countries with listed sites: Saudi Arabia
Registry dates and results: Start: 2027-01-01. Completion: 2028-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Recombinant Zoster Vaccine (Shingrix; RZV) (drug)
Semaglutide (Ozempic®) (drug)
Placebo (saline injection) (drug)

Where the study takes place — 1 listed sites

Ministry of Health Medical City
Riyadh, Saudi Arabia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Effects of Tirzepatide on Blood, Imaging and Breast Tissue Biomarkers

ClinicalTrials.gov · NCT06485089 · Registry updated: 2026-05-28

Condition / research focus: Obesity; Breast Cancer Risk
Sponsor: University of Kansas Medical Center
Countries with listed sites: United States
Registry dates and results: Start: 2024-09-14. Completion: 2026-03-25 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

tirzepatide (drug)

Where the study takes place — 2 listed sites

University of Kansas Medical Center
Kansas City, Kansas, United States
Site recruitment: Not reported
University of Kansas Medical Center Breast Cancer Prevention Center
Westwood, Kansas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2 / Phase 3RecruitingINTERVENTIONAL

A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar

ClinicalTrials.gov · NCT07284511 · Registry updated: 2026-05-27

Condition / research focus: Type 1 Diabetes; Type 1 Diabetes Mellitus; T1D; T1DM; T1DM - Type 1 Diabetes Mellitus
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre
Countries with listed sites: Canada · Switzerland
Registry dates and results: Start: 2026-05-19. Completion: 2029-01 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug) — also listed as: Mounjaro
Tandem Control-IQ Automated Insulin Delivery System (with Dexcom G7 CGM) (device) — also listed as: Control-IQ, Dexcom G7
Carbohydrate Counting (behavioral) — also listed as: Meal Announcement
No Meal Announcement (behavioral) — also listed as: Omission of Carbohydrate Counting

Where the study takes place — 4 listed sites

Institut de Recherches Cliniques de Montréal
Montreal, Quebec, Canada
Site recruitment: Not yet recruiting
McGill University Health Centre
Montreal, Quebec, Canada
Site recruitment: Not yet recruiting
Hygea Medical Clinic
Montreal, Quebec, Canada
Site recruitment: Recruiting
Insel Hospital, University Hospital Bern
Bern, Switzerland
Site recruitment: Not yet recruiting

Original record, eligibility, contacts and results →

Worldwide Study Finder

Find a study

Registry search results

Mazdutide for Adults With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial (DREAM-PRE)

Explore the world’s study registries

Worldwide

Africa

Americas

Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight

Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type 1 Diabetes

Effect of a Dietary Supplement on Hormones Involved in Appetite Regulation in Overweight and Obese Adults

Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation

Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy

Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes

A Study to Investigate the Pharmacokinetics of Different Formulations and Safety of AZD5004 in Healthy Participants Aged 18 to 55 Years

GLP-1 Therapy After Bariatric Surgery in Chinese Patients With Obesity

Antidiabetic Medications and Risk of Cancer

Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease

Role of Glucagon-like Peptide-1 Receptor Agonists in Menstrual Irregularities in Adolescent Females With Type 1 Diabetes Mellitus

Tirzepatide on Atrial Fibrillation Recurrence After Catheter Ablation in Patients With Obesity and HFpEF

Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity

Effects of Inulin on Cardiometabolic Risk Factors in Individuals Using Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA ) Medications for Weight Loss

Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes

Effect of GLP-1 Analogue ROSE-010 on Appetite in Overweight and Obese Subjects

SHIELD-T1D: Shingrix and GLP-1 Agonist for Beta-Cell Preservation in Recent-Onset Type 1 Diabetes.

Effects of Tirzepatide on Blood, Imaging and Breast Tissue Biomarkers

A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar

Asia

Middle East

Europe

Oceania